These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 36210563)
1. Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer. Wang TF Thromb Res; 2022 May; 213 Suppl 1():S66-S71. PubMed ID: 36210563 [TBL] [Abstract][Full Text] [Related]
2. The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer or supportive care therapies. Wang TF; Hill M; Mallick R; Chaudry H; Unachukwu U; Delluc A; Carrier M Thromb Res; 2023 Nov; 231():128-134. PubMed ID: 37857226 [TBL] [Abstract][Full Text] [Related]
3. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319 [TBL] [Abstract][Full Text] [Related]
4. Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis. Dong S; Zhang Y; Li Y; Li Y; Miao Y; Zhao R; Zhai S Ann Pharmacother; 2021 Apr; 55(4):430-439. PubMed ID: 32938202 [TBL] [Abstract][Full Text] [Related]
5. Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies. Swartz AW; Drappatz J Oncologist; 2021 May; 26(5):427-432. PubMed ID: 33523555 [TBL] [Abstract][Full Text] [Related]
6. Safety of anticoagulant treatment in cancer patients. Wilts IT; Bleker SM; Van Es N; Büller HR; Di Nisio M; Kamphuisen PW Expert Opin Drug Saf; 2015 Aug; 14(8):1227-36. PubMed ID: 26059964 [TBL] [Abstract][Full Text] [Related]
7. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer. Pritchard ER; Murillo JR; Putney D; Hobaugh EC J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375 [TBL] [Abstract][Full Text] [Related]
8. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer. Kirkilesis GI; Kakkos SK; Tsolakis IA Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186 [TBL] [Abstract][Full Text] [Related]
9. First-Line Therapies for VTE Treatment and Secondary Prophylaxis in Patients With Cancer: A New Direction. Vogel SM; Smith LV; Peterson EJ J Pharm Pract; 2020 Jun; 33(3):356-363. PubMed ID: 30541367 [TBL] [Abstract][Full Text] [Related]
10. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far? Voigtlaender M; Langer F Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916 [TBL] [Abstract][Full Text] [Related]
11. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer. Ueyama H; Miyashita H; Takagi H; Cruz C; Burger A; Briasoulis A; Kuno T J Thromb Thrombolysis; 2021 Jan; 51(1):102-111. PubMed ID: 32458316 [TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulants in patients with cancer. Bossaer JB; Covert KL Am J Health Syst Pharm; 2019 Jul; 76(14):1019-1027. PubMed ID: 31361880 [TBL] [Abstract][Full Text] [Related]
13. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194 [TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis. Ross JA; Miller MM; Rojas Hernandez CM Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037 [TBL] [Abstract][Full Text] [Related]
15. Treatment of Acute Venous Thromboembolism. Nair S; Garza N; George M; Kaatz S Med Clin North Am; 2020 Jul; 104(4):631-646. PubMed ID: 32505257 [TBL] [Abstract][Full Text] [Related]
16. Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT). Tsoukalas N; Brito-Dellan N; Font C; Butler T; Rojas-Hernandez CM; Butler T; Escalante C; Support Care Cancer; 2022 Oct; 30(10):8559-8573. PubMed ID: 35932318 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic drug-drug interactions with direct anticoagulants in the management of cancer-associated thrombosis. Van der Linden L; Vanassche T; Van Cutsem E; Van Aelst L; Verhamme P Br J Clin Pharmacol; 2023 Aug; 89(8):2369-2376. PubMed ID: 37170893 [TBL] [Abstract][Full Text] [Related]
18. Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review. Baysal M; Bayrak M; Eşkazan AE Expert Rev Hematol; 2023 Feb; 16(2):131-140. PubMed ID: 36709432 [TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants. Vedovati MC; Giustozzi M; Becattini C Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513 [TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Direct Oral Anticoagulant Therapy in Patients With Cancer. Fovel LM; Seabury RW; Miller CD; Darko W; Probst LA; Horvath L J Pharm Pract; 2021 Oct; 34(5):710-714. PubMed ID: 31888399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]